52 results about "Brain edema" patented technology

The present invention is directed to a method of inhibiting at least one of vascular leakage, inflammation and fibrosis in an animal by administering to the animal a vascular leakage inhibiting amount of a composition, wherein at a substantially higher amount the composition is effective in inhibiting angiogenesis, and wherein the anti-angiogenic activity of the composition is separate from the vascular leakage inhibiting activity of the composition. The animal experiencing at least one of vascular leakage, inflammation and fibrosis has a disease selected from the group consisting of diabetes, chronic inflammation, brain edema, arthritis, uvietis, macular edema, cancer, hyperglycemia, a kidney inflammatory disease, a disorder resulting in kidney fibrosis, a disorder of the kidney resulting in proteinuria, and combinations thereof. The composition capable of inhibiting at least one of vascular leakage, inflammation and fibrosis is selected from the group consisting of angiostatin, fragments of angiostatin, analogs or derivatives of angiostatin, kringle 5 of plasminogen, fragments of kringle 5 of plasminogen, analogs or derivatives of kringle 5 of plasminogen, pigment epithelium-derived factor, fragments of pigment epithelium-derived factor, analogs or derivatives of pigment epithelium-derived factor and combinations thereof.

It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

A method for clinically monitoring the intracranial edema without wound is disclosed. A low-frequency electric current flows through the craniocerebral surface to generate a current field. When the tissue structure in the current field changes, the electric current field is redistributed to reflect the change of intracranial edema, which is detected by phase change and displayed by computer and display device.

The invention relates to a device used for monitoring hydrocephalus and encephaledema. The device comprises a signal encoding generator, an emission electrode, a receiving electrode, a signal processing digital converter, an orthogonal regulator, a detector, a parameter assessment device, a resistance analyzer and an assessment instrument. The invention also relates to a method used for monitoring hydrocephalus and encephaledema, which comprises the following steps of: intruding into the lower part of the skull skin; emitting electromagnetic waves; carrying out amplification and filter processing on the received electromagnetic waves, and converting the electromagnetic waves into digital signals; carrying out orthogonalization processing on the digital signals; detecting synthetic signals and orthogonal signals of the electromagnetic waves; calculating the relative attenuation coefficients, the relative phase displacement, the transmission speed difference and the complex wave value K; calculating the complex impedance Z and capacitance; and assessing hydrocephalus and encephaledema. According to the invention, hydrocephalus and encephaledema situations can be monitored and assessed all day in a non-intrusive mode so as to reduce the treatment risks.

The invention relates to the field of medical technology, which discloses a new usage of a petasites tricholobus franch extract and the contained bakkenolide compound in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases. The biological activity tests show that, the petasites tricholobus franch extract and the contained bakkenolide compound can significantly reduce the encephalic necrosis percentage of the rats with local cerebral ischemia, improve the behavior score of the ischemic rats and alleviate volume of brain edema and cerebral infarction of the rats with ischemia reperfusion injury, thus prompting that the petasites tricholobus franch extract and the contained bakkenolide compound have significant protective effect on the cerebral ischemia injury. The petasites tricholobus franch extract and the contained bakkenolide compound can further significantly reduce the J-point displacement caused by ISO and the LDH level in plasma, significantly reduce the scope of myocardial ischemic myocardial infarction of the rats caused by coronary artery ligation and lower the LDH level in the plasma of the rats with the myocardial ischemia. As the petasites tricholobus franch extract and the contained bakkenolide compound have good effects on the prevention and the treatment for heart and brain ischemic diseases aspects, the petasitestricholobus franch extract and the contained bakkenolide compound can be used in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases, including coronary heart disease, cerebral ischemia, cerebral infarction (stroke), myocardial infarction and so on.

The invention discloses injection of mannite and glycerol, which contains mannite, glycerol and water for injection. Furthermore, the invention also discloses a method for preparing the injection, which comprises the following steps: taking the mannite and the glycerol, dissolving into the water for injection, filtering and filling. The injection of the mannite and the glycerol is clinically used for treating cerebrovascular diseases, brain trauma, cerebral tumors, intracranial inflammation and the diseases of acute and chronic intracranial hypertension, hydrocephalus and the like caused by other reasons. The injection of the mannite and the glycerol has the functions of lowering the intracranial pressure quickly and eliminating the hydrocephalus and can also avoid death because of acute renal failure caused by the injury of the kidney; the injection of the mannite and the glycerol suppresses the apoptosis of neural cells and achieves the function of protecting the brain; the function of lowering the intracranial pressure is stable and has long retention time; crystals occurring because of the change of the air temperature or in the processes of storage and transportation are eliminated; and the glycerol is used as a caloric agent and can improve and recover the energy metabolism of the important viscera of the heart, the brain, the kidney and the like during oxygen deficiency. The injection of the mannite and the glycerol is a very effective, stable and safe medicine for promoting urination and removing water clinically.

The invention relates to a brain resistance distribution diagram dynamic measurer and relative method, wherein said measurer comprises 16 driving measuring electrodes, digit synthesize sine signal source, sine constant current source, voltage/phase detecting circuit, high-speed A/D collector, high-speed microprocessor, and PC. Said method uses network topology, to treat the brain resistance data via mark value, to be shown at PC. The invention will not hurt detected user, to get the condition of brain.

Melatonin has an activity of treating or preventing brain edema. Thus, the invention relates to a pharmaceutical composition comprising melatonin as an active ingredient. And, the invention relates to use of melatonin in the preparation of a pharmaceutical composition comprising melatonin as an active ingredient.

A method to reduce brain injury and brain swelling includes performing active compression decompression cardiopulmonary resuscitation on an individual in a supine position. The individual's head, shoulders, and heart are elevated relative to the individual's lower body. The head is elevated to a height of between about 20 cm and 30 cm above the horizontal plane and the heart is elevated to a height of between about 3 cm and 10 cm above the horizontal plane. Chest compressions are performed on the individual and actively decompressing the individual's chest while the individual's head, shoulders, and heart are elevated. Intrathoracic pressure of the individual is regulated using an intrathoracic pressure regulation device both while the individual is in the supine position and while the individual's head, shoulders, and heart are elevated relative to the lower body, thereby reducing brain edema during CPR.

The invention relates to a traditional Chinese medicinal extract product prepared from traditional Chinese medicinal raw materials composed of root of large-flowered skullcap, cape jasmine and pseudo-ginseng, a traditional Chinese medicinal composition containing scutelloside, geniposide and panax notoginseng saponins, a medicine containing the traditional Chinese medicinal extract product or the traditional Chinese medicinal composition, and their clinical application. The traditional Chinese medicinal extract product, the traditional Chinese medicinal composition and the medicine containing the traditional Chinese medicinal extract product or the traditional Chinese medicinal composition can be used in emergency treatment and treatment of diseases such as cerebrovascular disease, intracranial infection, craniocerebral trauma, craniocerebral space-occupying lesion or intoxication and the like, which are mainly represented by brain edema.

The present invention is directed to a method of inhibiting at least one of vascular leakage, inflammation and fibrosis in an animal by administering to the animal a vascular leakage inhibiting amount of a composition, wherein at a substantially higher amount the composition is effective in inhibiting angiogenesis, and wherein the anti-angiogenic activity of the composition is separate from the vascular leakage inhibiting activity of the composition. The animal experiencing at least one of vascular leakage, inflammation and fibrosis has a disease selected from the group consisting of diabetes, chronic inflammation, brain edema, arthritis, uvietis, macular edema, cancer, hyperglycemia, a kidney inflammatory disease, a disorder resulting in kidney fibrosis, a disorder of the kidney resulting in proteinuria, and combinations thereof. The composition capable of inhibiting at least one of vascular leakage, inflammation and fibrosis is selected from the group consisting of angiostatin, fragments of angiostatin, analogs or derivatives of angiostatin, pigment epithelium-derived factor, fragments of pigment epithelium-derived factor, analogs or derivatives of pigment epithelium-derived factor and combinations thereof.

The invention discloses an application of artemisinin in the prevention and treatment of cerebral apoplexy. Artemisinin is low in side effect, and the neurological functions of an ischemic mouse witha cerebral ischemia reperfusion symptom are improved by activating an ERK1/2 signal channel in the brain of the mouse; and the encephaledema and oxidative damage of the ischemic mouse with the cerebral ischemia reperfusion symptom are relieved, the cerebral infarction area of the mouse with the cerebral ischemia reperfusion symptom is reduced, and the nerve cell apoptosis, loss and the like of themouse with the cerebral ischemia reperfusion symptom are reduced, so that artemisinin has positive effects on the improvement of cerebral apoplexy.

The embodiment of the invention discloses a preparation system and a preparation method of a rat brain injury animal model. The preparation system comprises a cushion ball, a sleeve, a weight and a plastic film, wherein the plastic film is arranged at the bottom in the sleeve; the cushion ball is arranged in the sleeve and is connected with the plastic film; and the weight is arranged in the sleeve and above the cushion ball. The system can realize the preparation of an animal model with brain injury, and the prepared animal model has good stability, good repeatability and long survival time;and through the arrangement of the plastic film, the system can avoided the fact that brain tissue is severely damaged and has brain edema caused by the fact that the cushion ball is directly acted onbrain tissue to penetrate through dura mater, and can further facilitate the taking out of the cushion ball.

The invention provides a pharmaceutical composition for treating traumatic brain injury and a preparation of the pharmaceutical composition. The pharmaceutical composition comprises edaravone, isoxsuprine and a pharmaceutically acceptable carrier. The pharmaceutical composition can improve the neurological function after cerebral trauma, reduce the encephaledema degree after cerebral trauma, inhibit nerve cell apoptosis and reduce microglial cell mediated central inflammatory response.

The invention relates to a method for producing the artificial skeleton in brain surgery. Wherein, it comprises that mixing hydroxypropyl cellulose, methyl silicon rubber, dolomol and medical talcum powder to be fed into particle maker; then mixing it with acroleic acid resin, polyethylene 2000F, skeleton resin, acacia gum and solidifier, to be fed into protrude machine to form material; feeding it into hydraulic shaper to be compressed into skeleton. The invention has high strength and stable property. It can float with the expansion of dropsy brain organism, and it can recover when the dropsy is released.

The invention belongs to the technical field of novel uses of drugs and in particular relates to an application of human albumin in preparing a drug for treating subarachnoid hemorrhage. Confirmed by experiments, the human albumin with a certain concentration can be used for improving early brain injuries after the subarachnoid hemorrhage, including relieving brain edema, lowering the death and the apoptosis of nerve cells and improving the damage to blood brain barrier, thus protecting brain tissues. The application can be used for preparing the drug for treating the subarachnoid hemorrhage, particularly to the drug for treating nerve injury after the subarachnoid hemorrhage.

The invention discloses application of glutathione (GSH) to preparation of a drug for preventing and treating central nervous system infection caused by salmonella typhimurium. A mouse meningitis model with the single-side ventricle being injected with the salmonella typhimurium SL1344 is provided, it is proven that the GSH has good treating activity, an experiment proves that the GSH can significantly prolong the median survival time of mice, the meningitis EAE score is increased, brain edema and inflammatory infiltration are relieved, and in addition, the GSH can relieve brain cell apoptosisby lowering phosphorylation of JNK.

An antelope brain-benefiting mixture comprises antelope horn, radix cyathulae, tortoise shell, figwort, bamboo shavings, alism orientale, polyporus, Tuckahoe, fried muscardine cadaver and full trichosanthes which are added in the following proportion by weight part: 8-12 grams of antelope horn, 140-160 grams of radix cyathulae, 90-110 grams of tortoise shell, 140-160 grams of figwort, 130-160 grams of bamboo shavings, 140-160 grams of alism orientale, 140-160 grams of polyporus, 140-160 grams of Tuckahoe, 110-130 grams of fried muscardine cadaver and 110-130 grams of full trichosanthes. The method for preparing the mixture comprises the following steps of frying, boiling, filtering and concentrating the medicinal materials according to the part by weight in order to obtain the antelope brain-benefiting mixture which is used for treating intracranial hypertentsion, brain edema and centric fever caused by the acute period of stroke, and has the efficacy of nourishing yin and suppressing the excessive yang, and restoring consciousness. The invention has the advantages of low cost and no toxic side effect.

The invention discloses an application of an effective component group of a thrombus-eliminating collateral-dredging formula in preparation of a medicine for treating cerebral hemorrhage. The cerebralhemorrhage comprises simple cerebral hemorrhage stroke, cerebral ischemia hemorrhage caused by hyperglycemia or hypertension after cerebral embolism, and hemorrhage caused by thrombolytic medicine treatment and other factors. Experimental research finds that an effective component group formed by active screening of components obtained by different extraction methods of the thrombus-eliminating and collateral-dredging formula can significantly reduce the volume of cerebral infarction and encephaledema of rats, improve neurological functions and protect blood-brain barrier damage caused by hyperglycemia, thereby reducing the risk and degree of hemorrhagic transformation during hyperglycemia. The effective component group of the thrombus-eliminating and collateral-dredging formula can be used for preparing medicines for treating cerebral hemorrhage and hemorrhage transformation caused by hyperglycemia, relieving secondary hemorrhage in ischemic areas and improving prognosis of patients.